drugset / Trial / NCT00319592

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX

NCT00319592

Phase 2 Completed 60 enrolled Sanofi PRA Health Sciences · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVax™-JE and JE-VAX® to the respective homologous virus strain and several wild types strains after completion of vaccination course.

Timeline

Start
2005-05
Primary completion
2006-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ChimeriVax™-JE Vaccine 0.5 ml Subcutaneous
Comparator JE-VAX® Vaccine 1 ml Subcutaneous

Indications